← Back to Search

Insulin Pump with Continuous Glucose Monitoring

Insulin Pump with Continuous Glucose Monitoring for Type 1 Diabetes

N/A
Waitlist Available
Research Sponsored by Medtronic Diabetes
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial tests the safety and effectiveness of an insulin pump and glucose monitor for adults and kids with type 1 diabetes.

Eligible Conditions
  • Type 1 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Effectiveness Endpoint for Age 18-80 - Percent of Time in Range (TIR 70-180 mg/dL)
Primary Effectiveness Endpoint for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL)
Primary Safety Endpoint for Age 18-80 - Change in HbA1c
+1 more
Secondary outcome measures
Secondary Effectiveness Endpoint 1 for Age 18-80 - Percent of Time in Hypoglycemia (< 54 mg/dL)
Secondary Effectiveness Endpoint 1 for Age 7-17 - Percent of Time in Hypoglycemia (< 54 mg/dL)
Secondary Effectiveness Endpoint 2 for Age 18-80 - Percent of Time in Range (TIR 70-180 mg/dL)
+1 more

Side effects data

From 2016 Phase 4 trial • 85 Patients • NCT01970241
21%
Hypoglycemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
NPH With Corticosteroid
Control

Trial Design

1Treatment groups
Experimental Treatment
Group I: MiniMed™ 780G system with DS5Experimental Treatment1 Intervention
Subjects with type 1 diabetes wearing the MiniMed™ 780G insulin pump in combination with the DS5 CGM.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Insulin Pump with Continuous Glucose Monitoring
2023
N/A
~250

Find a Location

Who is running the clinical trial?

Medtronic DiabetesLead Sponsor
67 Previous Clinical Trials
9,751 Total Patients Enrolled

Media Library

MiniMed™ 780G System With DS5 CGM (Insulin Pump with Continuous Glucose Monitoring) Clinical Trial Eligibility Overview. Trial Name: NCT05714059 — N/A
Type 1 Diabetes Research Study Groups: MiniMed™ 780G system with DS5
Type 1 Diabetes Clinical Trial 2023: MiniMed™ 780G System With DS5 CGM Highlights & Side Effects. Trial Name: NCT05714059 — N/A
MiniMed™ 780G System With DS5 CGM (Insulin Pump with Continuous Glucose Monitoring) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05714059 — N/A
Type 1 Diabetes Patient Testimony for trial: Trial Name: NCT05714059 — N/A
~111 spots leftby Jun 2025